Gilead Announced Earlier Continued Treatment With Bulevirtide Shows Clinical Benefit And Sustained Viral Decline With Prolonged Treatment In Patients Originally Considered Partial Or Non-Responders
Portfolio Pulse from Charles Gross
Gilead Sciences announced Week 96 results from the MYR301 Phase 3 clinical trial of Hepcludex (bulevirtide) for chronic hepatitis delta (HDV) infection treatment. The data presented at EASL Congress 2023 show clinical benefits and sustained viral decline in patients. Bulevirtide is the only approved treatment for HDV in the EU but not in the U.S.
June 23, 2023 | 8:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's Hepcludex (bulevirtide) demonstrates clinical benefits and sustained viral decline in Phase 3 trial for chronic hepatitis delta treatment, reinforcing its role as an effective treatment.
The positive results from the Phase 3 trial of Hepcludex (bulevirtide) indicate that the drug is effective in treating chronic hepatitis delta infection. This could lead to increased demand for the drug and potentially boost Gilead's revenues, especially if it gains approval in the U.S. market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100